Enervana Technologies LLC is an engineering firm founded by LSU faculty to develop and commercialize microsystem products, including a metal-based microchannel cooling system for electronic devices.  In 2009-10, Enervana was awarded a $100,000 SBIR Phase I Grant and a $50,000 SBIR Phase IB Grant from the National Science Foundation to assist in the development of the microchannel cooling system.

Esperance Pharmaceuticals Inc. is developing a new class of targeted anticancer drugs that selectively kills cancer cells without harming normal cells. This start-up company is based on technology jointly developed at LSU, Pennington Biomedical Research Center, and LSU AgCenter. 

JOBU Outdoors, LLC.’s revolutionary ATTRAXX with Sci-X^TM soft baits incorporate a chemical attractant and feeding stimulator developed by LSU Department of Biological Sciences professor John Caprio and a unique matrix developed by LSU Chemical Engineering professor James Henry.  The baits are currently being sold online and at fishing stores around the country. 

New Oil Resources was founded in 2008 by LSU faculty to commercialize a novel method for converting biomass to fuel.  The company is currently pursuing external funding and commercial partners.

Tesa Medical Inc. is a start-up company formed in 2008 to develop and commercialize a soft tissue fixation device used in anterior cruciate ligament (ACL) reconstruction.  This novel invention was made by researchers in the LSU School of Veterinary Medicine.  In addition to licensing the technology, the company will provide research funding to LSU.

VeroScience is committed to developing novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research.  Nearly 30 years ago, Drs. Anthony Cincotta and Al Meier began their research at LSU that lead to the discovery and commercialization of a new anti-diabetes drug, Cycloset^TM. Cycloset^TM was approved by the FDA in 2009 and is currently being sold by prescription as stand-alone or add-on treatment for Type-2 diabetes in adults.